About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
RGLS
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Regulus Therapeutics up 19% on raising $15M
- Regulus Therapeutics GAAP EPS of -$0.40 beats by $0.11
- Regulus Therapeutics GAAP EPS of -$0.50
- Regulus Therapeutics Q3 2022 Earnings Preview
- Regulus surges 15% after Phase 1 data for kidney disease candidate
- Regulus Therapeutics GAAP loss per share narrows
- Regulus Therapeutics Q2 2022 Earnings Preview
- Regulus Therapeutics GAAP EPS of -$0.05
- Regulus Therapeutics Q1 2022 Earnings Preview
- Regulus spikes as FDA clears trial for kidney disease candidate
- Regulus Therapeutics GAAP EPS of -$0.07
- Regulus Therapeutics Q4 2021 Earnings Preview
- Regulus to receive $34.6M through private placement of equity
- Regulus Therapeutics EPS misses by $0.02, revenue in-line
- Regulus Therapeutics Q3 2021 Earnings Preview
- Regulus falls 22% on decision to focus on another kidney disease candidate (update)
- Cantor initiates Regulus as overweight on microRNA technology platform; sees 147% upside
- Regulus Therapeutics EPS in-line
- Regulus Therapeutics reports additional RGLS4326 data in polycystic kidney disease
- Regulus updates results from early-stage trial for polycystic kidney disease